Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients

Hypertension

Volumn 64, Issue 2, 2014, Pages 431-437

  Seravalle, Gino ^a   Colombo, Manuela ^a,b   Perego, Paolo ^c   Giardini, Vittorio ^c   Volpe, Marco ^b   Dell'Oro, Raffaella ^b   Mancia, Giuseppe ^d,e   Grassi, Guido ^b,d,e,f  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c Chirurgia II ^*  (Poland)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e Centro Interuniversitario di Fisiologia Clinica e Ipertensione   (Italy)

^f IRCCS MULTIMEDICA   (Italy)

Author keywords

bariatric surgery; baroreflex; body weight; insulin resistance; leptin; obesity; sympathetic nervous system

Indexed keywords

GLUCOSE; INSULIN; LEPTIN;

ADULT; ARTICLE; BARIATRIC SURGERY; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEART BEAT; HEART RATE; HOMEOSTATIC MODEL ASSESSMENT INDEX; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; MICRONEUROGRAPHY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROGRAPHY; OBESITY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; SLEEVE GASTRECTOMY; SYMPATHETIC NERVE; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION;

BARIATRIC SURGERY; BAROREFLEX; BODY WEIGHT; INSULIN RESISTANCE; LEPTIN; OBESITY; SYMPATHETIC NERVOUS SYSTEM;

BARIATRIC SURGERY; BAROREFLEX; BLOOD PRESSURE; BODY MASS INDEX; FEMALE; HEART RATE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; OBESITY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84904473198     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02988     Document Type: Article

References (50)

1. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial-a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219-234.
2. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1-190, 215.
3. Marsk R, Näslund E, Freedman J, Tynelius P, Rasmussen F. Bariatric surgery reduces mortality in Swedish men. Br J Surg. 2010;97:877-883.
4. Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC, Nordmann AJ. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934.
5. To VT, Hüttl TP, Lang R, Piotrowski K, Parhofer KG. Changes in body weight, glucose homeostasis, lipid profiles, and metabolic syndrome after restrictive bariatric surgery. Exp Clin Endocrinol Diabetes. 2012;120:547-552.
6. Tzotzas T, Evangelou P, Kiortsis DN. Obesity, weight loss and conditional cardiovascular risk factors. Obes Rev. 2011;12:e282-e289.
7. Hofsø D, Nordstrand N, Johnson LK, Karlsen TI, Hager H, Jenssen T, Bollerslev J, Godang K, Sandbu R, Røislien J, Hjelmesaeth J. Obesityrelated cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2010;163:735-745.
8. Bobbioni-Harsch E, Bongard O, Habicht F, Weimer D, Bounameaux H, Huber O, Chassot G, Morel P, Assimacopoulos-Jeannet F, Golay A. Relationship between sympathetic reactivity and body weight loss in morbidly obese subjects. Int J Obes Relat Metab Disord. 2004;28:906-911.
9. Mark AL. Weight reduction for treatment of obesity-associated hypertension: nuances and challenges. Curr Hypertens Rep. 2007;9:368-372.
10. van de Borne P, Watrin I, Bouquegneau M, Gilles A, Houben JJ, Fery F, Degaute JP. Ambulatory blood pressure and neuroendocrine control after diet-assisted gastric restrictive surgery. J Hypertens. 2000;18:301-306.
11. Lips MA, de Groot GH, De Kam M, Wiezer R, Van Wagensveld BA, Luijten A, Pijl H, Burggraaf J. Autonomic nervous sytem activity in diabetic and healthy obese female subjects and the effect of distinct weight loss strategies. Eur J Endocrinol. 2013;169:383-390.
12. Pontiroli AE, Merlotti C, Veronelli A, Lombardi F. Effect of weight loss on sympatho-vagal balance in subjects with grade-3 obesity: restrictive surgery versus hypocaloric diet. Acta Diabetol. 2013;50:843-850.
13. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719-734.
14. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
15. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS, Cateliotti A. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354-1359.
16. Rouleau JL, Packer M, Moyé L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F. Prognostic value of neurohu-moral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583-591.
17. Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Prognostic rel-evance of pathological sympathetic activation after acute thromboembolic stroke. Neurology. 2001;57:833-838.
18. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension. 1993;21:618-623.
19. Lembo G, Capaldo B, Rendina V, Iaccarino G, Napoli R, Guida R, Trimarco B, Saccá L. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am J Physiol. 1994;266(2 pt 1):E242-E247.
20. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
21. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25(4 pt 1):560-563.
22. Grassi G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F, Gamba PL, Mancia G. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48:1359-1365.
23. Grassi G, Seravalle G, Colombo M, Bolla G, Cattaneo BM, Cavagnini F, Mancia G. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation. 1998;97:2037-2042.
24. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
25. Park SH, Shub C, Nobrega TP, Bailey KR, Seward JB. Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography. J Am Soc Echocardiogr. 1996;9:119-128.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
27. Hjemdahl P, Daleskog M, Kahan T. Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method. Life Sci. 1979;25:131-138.
28. Ikeda I, Iinuma K, Takai M, Yanagawa Y, Kurata K, Ogihara T, Kumahara Y. Measurement of plasma renin activity by a simple solid phase radioimmunoassay. J Clin Endocrinol Metab. 1982;54:423-428.
29. Ojima M, Aida M, Kambegawa A. Simultaneous determination of plasma 11-deoxycorticosterone, 18-hydroxy-11-deoxycorticosterone, and aldosterone in man. Tohoku J Exp Med. 1978;124:367-379.
30. Scherrer U, Randin D, Tappy L, Vollenweider P, Jequier E, Nicod P. Body fat and sympathetic nerve activity in healthy humans. Circulation. 1994;89:2634-2640.
31. Curry TB, Somaraju M, Hines CN, Groenewald CB, Miles JM, Joyner MJ, Charkoudian N. Sympathetic support of energy expenditure and sympathetic nervous system activity after gastric bypass surgery. Obesity (Silver Spring). 2013;21:480-485.
32. Esler M. The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol (1985). 2010;108:227-237.
33. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009; 54:690-697.
34. DiBona GF. Sympathetic nervous system and hypertension. Hypertension. 2013;61:556-560.
35. De Angelis K, Senador DD, Mostarda C, Irigoyen MC, Morris C. Sympathetic overactivity precedes metabolic dysfunction in a fructose model of glucose intolerance. Am J Physiol. 2012;302:R950-957.
36. Ng KW. Regulation of glucose metabolism and the skeleton. Clin Endocrinol (Oxf). 2011;75:147-155.
37. Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res. 2012;35:4-16.
38. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension. 2002;39(2 pt 2):496-501.
39. Mark AL. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol. 2013;305:R566-R581.
40. Machleidt F, Simon P, Krapalis AF, Hallschmid M, Lehnert H, Sayk F. Experimental hyperleptinemia acutely increases vasoconstrictory sympathetic nerve activity in healthy humans. J Clin Endocrinol Metab. 2013;98:E491-E496.
41. Mancia G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Grassi G. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens Suppl. 2006;24:S51-S56.
42. Lembo G, Napoli R, Capaldo B, Rendina V, Iaccarino G, Volpe M, Trimarco B, Saccà L. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J Clin Invest. 1992;90:24-29.
43. Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension. 1992;19(6 pt 2):621-627.
44. Mancia G, Mark AL. Arterial baroreflexes in humans. In: Shepherd JT, Abboud FM, eds. Handbook of Physiology, Section 2: The Cardiovascular System. Bethesda, MD: American Physiological Society; 1983:755-793.
45. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev. 1990;70:963-985.
46. Lambert E, Lambert G, Ika-Sari C, Dawood T, Lee K, Chopra R, Straznicky N, Eikelis N, Drew S, Tilbrook A, Dixon J, Esler M, Schlaich MP. Ghrelin modulates sympathetic nervous system activity and stress response in lean and overweight men. Hypertension. 2011;58:43-50.
47. Anderson B, Switzer NJ, Almamar A, Shi X, Birch DW, Karmali S. The impact of laparoscopic sleeve gastrectomy on plasma ghrelin levels: a systematic review. Obes Surg. 2013;23:1476-1480.
48. Gordon T, Kannel WB. Obesity and cardiovascular diseases: the Framingham study. Clin Endocrinol Metab. 1976;5:367-375.
49. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA. 1978;240:1607-1610.
50. Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death. Arch Intern Med. 1987;147:1725-1728.